StockData
Regentis Biomaterials Ltd. logo

Regentis Biomaterials Ltd. (RGNT) shareholders

RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 24, 2026Score 1/30
$1.14−0.08 (-6.56%)

Close on Nov 18, 2026Market cap $5.90MP/E –Yield –

Ownership

Who owns Regentis Biomaterials's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Rosalind Advisors, Inc.
Joint filing with Salamon Steven A J (9.90%), Aharon Gil (9.90%) and 1 more
1,428,5709.90%13G (passive)Jun 30, 2026
Dr. Ehud Geller
Joint filing with Medica III Investments (International) L.P. (23.20%), Medica III Investments (Israel) L.P. (23.20%) and 4 more
1,332,86723.20%13G (passive)Dec 31, 2025

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Ehud GellerChief Executive Officer, Director––Jul 13, 2026
Galit ReskeChief Medical Officer––Mar 30, 2026
Arie GordashnikovChief Accounting Officer––Mar 18, 2026
Ori GonChief Financial Officer––Mar 18, 2026
Susan PHD Alpert MDDirector––Jul 13, 2026
Pini Ben-ElazarDirector128,6662.48%Jul 13, 2026
Efraim Cohen-AraziDirector––Jul 13, 2026
Jeff DykanDirector270,4735.22%Jul 13, 2026
Keith ValentineDirector––Jul 13, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.19%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-46.0%
From 0M shares
Short volume, 20 days
42.8%
Of volume reported to FINRA

Shares sold short, last 11 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Regentis Biomaterials's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,363 shares on Oct 6, 2026 over the last 90 days.

See a number that looks wrong?